Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genesBAXEVANIS, Constantin N; PAPAMICHAIL, Michael.Cancer immunology and immunotherapy. 2004, Vol 53, Num 10, pp 893-903, issn 0340-7004, 11 p.Article

Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapyBAXEVANIS, Constantin N; PEREZ, Sonia A; PAPAMICHAIL, Michael et al.Cancer immunology and immunotherapy. 2009, Vol 58, Num 3, pp 317-324, issn 0340-7004, 8 p.Article

Therapeutic cancer vaccines: a long and winding road to successBAXEVANIS, Constantin N; PAPAMICHAIL, Michael; PEREZ, Sonia A et al.Expert review of vaccines. 2014, Vol 13, Num 1, pp 131-144, issn 1476-0584, 14 p.Article

Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant miceGRITZAPIS, Angelos D; VOUTSAS, Ioannis F; BAXEVANIS, Constantin N et al.Cancer immunology and immunotherapy. 2012, Vol 61, Num 3, pp 397-407, issn 0340-7004, 11 p.Article

HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3⁺CD56⁺ (natural killer T) lymphocytesBAXEVANIS, Constantin N; GRITZAPIS, Angelos D; TSITSILONIS, Ourania E et al.International journal of cancer. 2002, Vol 98, Num 6, pp 864-872, issn 0020-7136Article

Growth inhibition of breast cancer cell lines overexpressing Her2/neu by a novel internalized fully human Fab antibody fragmentBELIMEZI, Maria M; PAPANASTASSIOU, Danai; MERKOURI, Efrossini et al.Cancer immunology and immunotherapy. 2006, Vol 55, Num 9, pp 1091-1099, issn 0340-7004, 9 p.Article

Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapyBAXEVANIS, Constantin N; SOTIROPOULOU, Panagiota A; SOTIRIADOU, Nectaria N et al.Cancer immunology and immunotherapy. 2004, Vol 53, Num 3, pp 166-175, issn 0340-7004, 10 p.Conference Paper

Effect of the simultaneous administration of glucocorticoids and IL-15 on human NK cell phenotype, proliferation and functionMOUSTAKI, Ardiana; ARGYROPOULOS, Kimon V; BAXEVANIS, Constantin N et al.Cancer immunology and immunotherapy. 2011, Vol 60, Num 12, pp 1683-1695, issn 0340-7004, 13 p.Article

Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumorsGRITZAPIS, Angelos D; SOTIRIADOU, Nectaria N; PAPAMICHAIL, Michael et al.Cancer immunology and immunotherapy. 2004, Vol 53, Num 11, pp 1027-1040, issn 0340-7004, 14 p.Article

Natural killer lymphocytes: biology, development, and functionPAPAMICHAIL, Michael; PEREZ, Sonia A; GRITZAPIS, Angelos D et al.Cancer immunology and immunotherapy. 2004, Vol 53, Num 3, pp 176-186, issn 0340-7004, 11 p.Conference Paper

Peptide Vaccination Breaks Tolerance to HER-2/neu by Generating Vaccine-Specific FasL⁺ CD4⁺ T Cells: First Evidence for Intratumor Apoptotic Regulatory T CellsGRITZAPIS, Angelos D; VOUTSAS, Loannis F; LEKKA, Eftychia et al.Cancer research (Chicago, Ill.). 2010, Vol 70, Num 7, pp 2686-2696, issn 0008-5472, 11 p.Article

A novel quantitative flow cytometric method for measuring glucocorticoid receptor (GR) in cell lines : Correlation with the biochemical determination of GRVOUTSAS, Ioannis F; GRITZAPIS, Angelos D; ALEXIS, Michael N et al.Journal of immunological methods. 2007, Vol 324, Num 1-2, pp 110-119, issn 0022-1759, 10 p.Article

Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivoGRITZAPIS, Angelos D; MAHAIRA, Louisa G; PEREZ, Sonia A et al.Cancer research (Baltimore). 2006, Vol 66, Num 10, pp 5452-5460, issn 0008-5472, 9 p.Article

A novel culture environment for generating mature human dentritic cells from peripheral blood CD14⁺cellsTSIATAS, Marinos L; GRITZAPIS, Angelos D; CACOULLOS, Nike T et al.Anticancer research. 2001, Vol 21, Num 2A, pp 1199-1206, issn 0250-7005Article

Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapyLEKKA, Eftychia; GRITZAPIS, Angelos D; PEREZ, Sonia A et al.Cancer immunology and immunotherapy. 2010, Vol 59, Num 5, pp 715-727, issn 0340-7004, 13 p.Article

Efficacy of novel culture environments on the ex vivo expansion kinetics of cord blood progenitor cellsCACOULIOS, Nike T; GRITZAPIS, Angelos D; TSITSILONIS, Athanasios E et al.Haematologica (Roma). 2002, Vol 87, Num 3, pp 320-321, issn 0390-6078Article

Induction of potent CD4⁺ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-key moiety of the invariant chainVOUTSAS, Ioannis F; GRITZAPIS, Angelos D; MAHAIRA, Louisa G et al.International journal of cancer. 2007, Vol 121, Num 9, pp 2031-2041, issn 0020-7136, 11 p.Article

In vitro and in vivo antitumor activity of a mouse CTL hybridoma expressing chimeric receptors bearing the single chain Fv from HER-2/neu- specific antibody and the γ-chain from Fc(ε) RIMAMALAKI, Avgi; GRITZAPIS, Angelos D; KRETSOVALI, Androniki et al.Cancer immunology and immunotherapy. 2003, Vol 52, Num 8, pp 513-522, issn 0340-7004, 10 p.Article

Natural CD8⁺ T-cell responses against MHC class I epitopes of the HER-2/neu oncoprotein in patients with epithelial tumorsSOTIROPOULOU, Panagiota A; PEREZ, Sonia A; VOELTER, Volfgang et al.Cancer immunology and immunotherapy. 2003, Vol 52, Num 12, pp 771-779, issn 0340-7004, 9 p.Article

A New Era in Anticancer Peptide VaccinesPEREZ, Sonia A; VON HOFE, Eric; KALLINTERIS, Nikoletta L et al.Cancer. 2010, Vol 116, Num 9, pp 2071-2080, issn 0008-543X, 10 p.Article

HER-2/neu (657-665) represents an immunogenic epitope of HER-2/neu oncoprotein with potent antitumor propertiesGRITZAPIS, Angelos D; FRIDMAN, Arthur; PEREZ, Sonia A et al.Vaccine. 2010, Vol 28, Num 1, pp 162-170, issn 0264-410X, 9 p.Article

Quantitative fluorescence cytometric measurement of estrogen and progesterone receptors: correlation with the hormone binding assayGRITZAPIS, Angelos D; BAXEVANIS, Constantin N; MISSITZIS, Ioannis et al.Breast cancer research and treatment. 2003, Vol 80, Num 1, pp 1-13, issn 0167-6806, 13 p.Article

Increased frequency of CD4⁺ cells expressing CD161 in cancer patientsILIOPOULOU, Eleni G; KARAMOUZIS, Michalis V; MISSITZIS, Ioannis et al.Clinical cancer research. 2006, Vol 12, Num 23, pp 6901-6909, issn 1078-0432, 9 p.Article

HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4⁺T cell clonesPEREZ, Sonia A; SOTIROPOULOU, Panagiota A; SOTIRIADOU, Nectaria N et al.Cancer immunology and immunotherapy. 2002, Vol 50, Num 11, pp 615-624, issn 0340-7004Article

A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancerILIOPOULOU, Eleni G; KOUNTOURAKIS, Panteleimon; KARAMOUZIS, Michalis V et al.Cancer immunology and immunotherapy. 2010, Vol 59, Num 12, pp 1781-1789, issn 0340-7004, 9 p.Article